<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261312</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-110-01</org_study_id>
    <nct_id>NCT01261312</nct_id>
  </id_info>
  <brief_title>SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1-2 dose escalation randomized study in patients with intermediate or high risk&#xD;
      myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation&#xD;
      Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110&#xD;
      with two dosing schedules in MDS and AML patients while the Dose Expansion Segment will&#xD;
      further evaluate safety and efficacy at the biological effective dose (BED) or maximum&#xD;
      tolerated dose (MTD)as defined in the Dose Escalation Segment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the BED and MTD is determined in the Dose Escalation Segment, the Dose Expansion Segment&#xD;
      will randomize patients with MDS, treatment naïve elderly AML, and relapsed/refractory AML&#xD;
      patients to receive the BED or MTD dose. Relapsed/refractory AML patients may also receive&#xD;
      SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose&#xD;
      Escalation Segment using the 5-daily regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation Segment (Safety Lead-in): Determine the optimal BED or MTD and the frequency of drug administration.</measure>
    <time_frame>Assessed at the end of Course 1 (4 weeks) for each dose cohort.</time_frame>
    <description>Number of patients with adverse events.&#xD;
Incidence of dose limiting toxicities.&#xD;
Degree of hypomethylation as measured by LINE-1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion Segment: Assess the activity of SGI-110 as measured by overall remission rate.</measure>
    <time_frame>12 Months</time_frame>
    <description>Overall survival measured in weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetic profile of SGI-110 and decitabine.</measure>
    <time_frame>Assessed at the end of Course 1 (4 weeks) for each cohort.</time_frame>
    <description>Cmax, Cmin, AUC and other secondary PK parameters of SGI-110 and decitabine in patients during Course 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration, hematological improvements and transfusion independence rates.</measure>
    <time_frame>12 months</time_frame>
    <description>Assess remission duration, hematological improvement and transfusion independence rates as measured by weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine epigenetic modulation in peripheral blood and bone marrow samples.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>MDS</condition>
  <condition>CMML</condition>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Daily Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 daily x5 dosing on a 28-day course&#xD;
SGI-110 daily x10 dosing on a 28-day course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weekly Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 weekly dosing for three weeks on a 28-day course&#xD;
SGI-110 twice weekly dosing for three weeks on a 28-day course</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110</intervention_name>
    <description>SGI-110 subcutaneous injection administered on Days 1-5&#xD;
SGI-110 subcutaneous injection administered on Days 1-5 and 8-12</description>
    <arm_group_label>Daily Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110</intervention_name>
    <description>SGI-110 administered weekly on Days 1, 8 and 15&#xD;
SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18</description>
    <arm_group_label>Weekly Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women, 18 years of age or older, with a confirmed diagnosis of international&#xD;
             prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS&#xD;
             including Chronic Myelomonocytic Leukemia (CMML) or AML.&#xD;
&#xD;
               -  In the Dose Escalation Segment, patients who are refractory, relapsed, or&#xD;
                  unresponsive to standard treatment.&#xD;
&#xD;
               -  In the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS&#xD;
                  subjects (including CMML), and intermediate-2 or high-risk MDS subjects&#xD;
                  (including CMML) relapsed or refractory to prior HMA treatment are allowed, and&#xD;
                  treatment-naïve AML subjects who are at least 65 years of age will be allowed if&#xD;
                  they also have at least one of the following criteria&#xD;
&#xD;
                    -  AML secondary to MDS, chemotherapy, or radiation therapy&#xD;
&#xD;
                    -  poor cytogenetics&#xD;
&#xD;
                    -  pre-existing clinically significant dysfunction of the heart or Chronic&#xD;
                       Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
                    -  poor performance status, Eastern Cooperative Oncology Group (ECOG), of 2&#xD;
&#xD;
          2. Eastern ECOG performance status of 0 to 2.&#xD;
&#xD;
          3. Adequate organ function.&#xD;
&#xD;
          4. Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease&#xD;
             (GVHD) and must be ≥ 2 weeks off immunosuppressive therapy.&#xD;
&#xD;
          5. No major surgery within 4 weeks of first dose of SGI-110.&#xD;
&#xD;
          6. No chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for&#xD;
             nitrosoureas and 8 weeks for bone marrow transplantation) with the exception of&#xD;
             hydroxyurea which will be allowed during course 1 of treatment.&#xD;
&#xD;
          7. Sign an approved informed consent form for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the Dose Expansion Segment, which includes the 10-day regimen, subjects who have&#xD;
             received 2 complete full dose cycles or more of a hypomethylating agent (HMA)&#xD;
             decitabine or azacitidine (except for intermediate-2 or high-risk MDS subjects&#xD;
             (including CMML) relapsed or refractory to prior HMA treatment).&#xD;
&#xD;
          2. Acute promyelocytic leukemia (M3 classification).&#xD;
&#xD;
          3. Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer from which the patient has been&#xD;
             disease free for at least 3 years.&#xD;
&#xD;
          4. Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or&#xD;
             organ system dysfunction which, in the investigator's opinion, could compromise the&#xD;
             patient's safety, or put the study outcomes at risk.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus (HIV) or active infection with hepatitis&#xD;
             C virus (HCV) or hepatitis B virus (HBV).&#xD;
&#xD;
          6. Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.&#xD;
&#xD;
          7. With the exception of treatment-naïve elderly AML patients, patients with uncontrolled&#xD;
             congestive heart failure (CHF), coronary heart disease (CAD), chronic obstructive&#xD;
             pulmonary disease (COPD), or left ventricular ejection fraction (LVEF) of ≤ 50% are&#xD;
             excluded, symptomatic or uncontrolled arrhythmias or on continuous corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <disposition_first_submitted>May 22, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>May 22, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 31, 2019</disposition_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGI-110</keyword>
  <keyword>DNA Hypomethylating Agent</keyword>
  <keyword>Intermediate 1, Intermediate 2, CMML or High Risk MDS</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guadecitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

